Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
C-Suite · BofD · VPs/SVPs
All the data Denali Therapeutics Inc. presents was sourced from the latest proxy filing.
The proxy statement is the most reliable resource when it comes to compensation breakdowns and other information where an audited is preferred.
Shows the total compensation per mentioned executive and board director.
Each datapoint refers the most recent appearance of the corresponding person.
C-Suite, BofD and VPs/SVPs Beta
The proxy statement is the most reliable resource when it comes to compensation breakdowns and other information where an audited is preferred.
C-Suite and VPs/SVPs
Board of Directors (BofD)
Proxy Sections
Our core belief is in providing transparent validation principles, so here are the document sections we used for retrieving the data over-time:Total Compensation ($)
Add Series
Each datapoint refers the most recent appearance of the corresponding person.